Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Oct 2019 Status changed to recruiting.
- 26 Sep 2019 This trial has been completed in Bulgaria, according to European Clinical Trials Database.